Market Research Logo

Head and Neck Cancers: Epidemiology Forecast to 2026

Head and Neck Cancers: Epidemiology Forecast to 2026

Summary

Head and neck cancers usually begin in the squamous cells that line the moist mucosal surfaces of the tissues and organs of the head and neck-more than 83% of all oral cavity and pharynx cancers are squamous cell carcinomas. They are the ninth most common malignancy in the world, with high mortality rates in the developing countries.

10-year epidemiological forecasts of the diagnosed incident cases of HNCs are provided. HNCs are grouped into the following, in this report -

1. Cancers of the lip, oral cavity, pharynx, and larynx cancer (ICD-10 = C00-C06, C09-C10, C12-C14, and C32)
2. Oropharynx cancer (ICD-10 = C10)
3. Nasopharynx cancer (ICD-10 = C11)
4. Other head and neck cancer sites - salivary gland and nose, sinuses, and other related structures cancer (ICD-10 = C07-C08 and C30-C31)

To forecast the diagnosed incident cases and the five-year diagnosed prevalent cases of HNCs in the 7MM, GlobalData epidemiologists selected nationally representative, population-based studies or cancer registries that provided the diagnosed incidence or observed or relative survival rates for these cancers in the 7MM. GlobalData estimate that the diagnosed incident cases of HNCs in the 7MM will increase from 154,300 cases in 2016 to 177,034 cases in 2026, at an Annual Growth Rate (AGR) of 1.47% over the forecast period. Throughout the forecast period, the US will have the highest number of diagnosed incident cases of HNCs, followed by Japan.

Scope

  • The Head and Neck Cancers Epidemiology report provides an overview of the risk factors and global trends of head and neck cancers in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • 10-year epidemiological forecasts of the diagnosed incident cases of HNCs are provided and segmented into the following groups: cancers of the lip, oral cavity, pharynx, and larynx cancer; oropharynx cancer; nasopharynx cancer; and other sites. Histology distribution and, clinical stage at diagnosis, risk factors, and diagnosed five-year prevalent cases are available for some of the groups.
  • The head and neck cancers epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy

The head and neck cancers epidemiology report will allow you to -
  • Develop business strategies by understanding the trends shaping and driving the global head and neck cancers market.
  • Quantify patient populations in the global head and neck cancers market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for head and neck cancers therapeutics in each of the markets covered.
  • Understand magnitude of patient groups in each of the cancer subgroups and their relevant patient characteristics.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Head and Neck Cancers: Executive Summary
2.1 Related Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods - Population
3.4.3 Forecast Assumptions and Methods - Diagnosed Incident Cases of HNCs
3.4.4 Forecast Assumptions and Methods - Five-Year Diagnosed Prevalent Cases of HNCs
3.4.5 Forecast Assumptions and Methods - Diagnosed Incident Cases of HNCs by Histology Distribution
3.4.6 Forecast Assumptions and Methods - Diagnosed Incident Cases of HNC by Clinical Stages at Diagnosis for Squamous Cell Carcinoma
3.4.7 Forecast Assumptions and Methods - Diagnosed Incident Cases of Oropharynx Cancer by Risk Factor (HPV+ and HPV-)
3.4.8 Forecast Assumptions and Methods - Diagnosed Incident Cases of Nasopharynx Cancer by Risk Factor (EBV+)
3.5 Epidemiological Forecast for HNCs (2016-2026)
3.5.1 Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer
3.5.2 Age-Specific Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer
3.5.3 Sex-Specific Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer
3.5.4 Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer by Histology Distribution
3.5.5 Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer by Clinical Stage at Diagnosis for Squamous Cell Carcinoma
3.5.6 Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer
3.5.7 Diagnosed Incident Cases of Oropharynx Cancer by Histology Distribution and by Risk Factor (HPV)
3.5.8 Diagnosed Incident Cases of Nasopharynx Cancer by Histology Distribution and by Risk Factor (EBV)
3.5.9 Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer
3.5.10 Age-Specific Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer
3.5.11 Sex-Specific Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer
3.5.12 Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer by Histology Distribution
3.5.13 Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer by Clinical Stage at Diagnosis for Squamous Cell Carcinoma
3.5.14 Five-Year Diagnosed Prevalent Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of the Analysis
3.6.3 Strengths of the Analysis
4 Appendix
4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologist
4.2.2 Reviewers
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About GlobalData
4.4 Contact Us
4.5 Disclaimer
1.1 List of Tables
Table 1: Risk Factors and Comorbid Conditions Associated with HNCs
Table 2: 7MM, Diagnosed Incident Cases of Oropharynx Cancer by Histology Distribution and by Risk Factor (HPV), Both Sexes, Ages ≥18 Years, N, 2016
Table 3: 7MM, Diagnosed Incident Cases of Nasopharynx Cancer by Histology Distribution and by Risk Factor (EBV+), Both Sexes, Ages ≥18 Years, N, 2016
1.2 List of Figures
Figure 1: 7MM, Diagnosed Incident Cases of HNCs, Both Sexes, Ages ≥18 Years, N, 2016 and 2026
Figure 2: 7MM, Age-Standardized Diagnosed Incidence of Lip, Oral Cavity, Pharynx, and Larynx Cancer (Cases per 100,000 Population), Men, Ages ≥18 Years, 2016-2026
Figure 3: 7MM, Age-Standardized Diagnosed Incidence of Lip, Oral Cavity, Pharynx, and Larynx Cancer (Cases per 100,000 Population), Women, Ages ≥18 Years, 2016-2026
Figure 4: 7MM, Age-Standardized Diagnosed Incidence of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer (Cases per 100,000 Population), Men, Ages ≥18 Years, 2016-2026
Figure 5: 7MM, Age-Standardized Diagnosed Incidence of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer (Cases per 100,000 Population), Women, Ages ≥18 Years, 2016-2026
Figure 6: 7MM, Sources Used, Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer; Oropharynx Cancer; Nasopharynx Cancer; Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer
Figure 7: 7MM, Sources Used, Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer; Oropharynx Cancer; Nasopharynx Cancer by Histology Distribution
Figure 8: 7MM, Sources Used, Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer by Histology Distribution
Figure 9: 7MM, Sources Used, Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer by Clinical Stage at Diagnosis for Squamous Cell Carcinoma
Figure 10: 7MM, Sources Used, Diagnosed Incident Cases of Oropharynx Cancer; Nasopharynx Cancer; Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer by Clinical Stage at Diagnosis for Squamous Cell Carcinoma
Figure 11: 7MM, Sources Used, Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer
Figure 12: 7MM, Sources Used, Five-Year Diagnosed Prevalent Cases of Nasopharynx Cancer; Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer
Figure 13: 7MM, Sources Used, Diagnosed Incident Cases of Oropharynx Cancer by Risk Factor (HPV+ and HPV-)
Figure 14: 7MM, Sources Used, Diagnosed Incident Cases of Nasopharynx Cancer by Risk Factor (EBV+)
Figure 15: 7MM, Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer, Both Sexes, Ages ≥18 Years, N, 2016
Figure 16: 7MM, Age-Specific Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer, Both Sexes, N, 2016
Figure 17: 7MM, Sex-Specific Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer, Ages ≥18 Years, N, 2016
Figure 18: 7MM, Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer by Histology Distribution, Both Sexes, Ages ≥18 Years, N, 2016
Figure 19: 7MM, Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer by Clinical Stage at Diagnosis for Squamous Cell Carcinoma, Both Sexes, Ages ≥18 Years, N, 2016
Figure 20: 7MM, Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer, Both Sexes, Ages ≥18 Years, N, 2016
Figure 21: 7MM, Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer, Both Sexes, Ages ≥18 Years, N, 2016
Figure 22: 7MM, Age-Specific Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer, Both Sexes, Ages ≥18 Years, N, 2016
Figure 23: 7MM, Sex-Specific Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer, Ages ≥18 Years, N, 2016
Figure 24: 7MM, Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer by Histology Distribution, Both Sexes, Ages ≥18 Years, N, 2016
Figure 25: 7MM, Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer by Clinical Stage at Diagnosis for Squamous Cell Carcinoma, Both Sexes, Ages ≥18 Years, N, 2016
Figure 26: 7MM, Five-Year Diagnosed Prevalent Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer, Both Sexes, Ages ≥18 Years, N, 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report